EIF2AK3 and melanoma: Similar to our finding, Ma et al. reported that treatment with BRAF inhibitor induces the translocation of mutant BRAF to the ER and enhances BiP/GRP78 binding to mutant BRAF, sequestrating the release and activation of PERK and mediating melanoma drug resistance30.